Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma.

Pal SK, Drabkin HA, Reeves JA, Hainsworth JD, Hazel SE, Paggiarino DA, Wojciak J, Woodnutt G, Bhatt RS.

Cancer. 2017 Feb 15;123(4):576-582. doi: 10.1002/cncr.30393. Epub 2016 Oct 11.

2.

Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide.

Liu S, Desharnais J, Sahasrabudhe PV, Jin P, Li W, Oates BD, Shanker S, Banker ME, Chrunyk BA, Song X, Feng X, Griffor M, Jimenez J, Chen G, Tumelty D, Bhat A, Bradshaw CW, Woodnutt G, Lappe RW, Thorarensen A, Qiu X, Withka JM, Wood LD.

Sci Rep. 2016 May 17;6:26071. doi: 10.1038/srep26071.

3.

Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody.

Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, Li L, Jin P, Matin MJ, Huyghe B, Talukdar S, Bradshaw CW, Palanki M, Violand BN, Woodnutt G, Lappe RW, Ogilvie K, Levin N.

J Pharmacol Exp Ther. 2013 Aug;346(2):270-80. doi: 10.1124/jpet.113.204420. Epub 2013 May 29.

PMID:
23720456
4.

Peptide-conjugation induced conformational changes in human IgG1 observed by optimized negative-staining and individual-particle electron tomography.

Tong H, Zhang L, Kaspar A, Rames MJ, Huang L, Woodnutt G, Ren G.

Sci Rep. 2013;3:1089. doi: 10.1038/srep01089. Epub 2013 Jan 21.

5.

Antitumor efficacy of a thrombospondin 1 mimetic CovX-body.

Li L, Leedom TA, Do J, Huang H, Lai J, Johnson K, Osothprarop TF, Rizzo JD, Doppalapudi VR, Bradshaw CW, Lappe RW, Woodnutt G, Levin NJ, Pirie-Shepherd SR.

Transl Oncol. 2011 Aug;4(4):249-57. Epub 2011 Aug 1.

6.

Evolution of potent and stable placental-growth-factor-1-targeting CovX-bodies from phage display peptide discovery.

Bower KE, Lam SN, Oates BD, Del Rosario JR, Corner E, Osothprarop TF, Kinhikar AG, Hoye JA, Preston RR, Murphy RE, Campbell LA, Huang H, Jimenez J, Cao X, Chen G, Ainekulu ZW, Datt AB, Levin NJ, Doppalapudi VR, Pirie-Shepherd SR, Bradshaw C, Woodnutt G, Lappe RW.

J Med Chem. 2011 Mar 10;54(5):1256-65. doi: 10.1021/jm101226k. Epub 2011 Jan 31.

PMID:
21280651
7.

Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.

Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, Doppalapudi VR, Pirie-Shepherd S, Levin N, Bradshaw C, Woodnutt G, Lappe R, Bhat A.

Clin Cancer Res. 2011 Mar 1;17(5):1001-11. doi: 10.1158/1078-0432.CCR-10-2317. Epub 2011 Jan 13.

8.

Chemical generation of bispecific antibodies.

Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, Desharnais J, Hagen C, Levin NJ, Shields MJ, Parish M, Murphy RE, Del Rosario J, Oates BD, Lai JY, Matin MJ, Ainekulu Z, Bhat A, Bradshaw CW, Woodnutt G, Lerner RA, Lappe RW.

Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22611-6. doi: 10.1073/pnas.1016478108. Epub 2010 Dec 13.

9.

Targeting the ANGPT-TIE2 pathway in malignancy.

Huang H, Bhat A, Woodnutt G, Lappe R.

Nat Rev Cancer. 2010 Aug;10(8):575-85. doi: 10.1038/nrc2894. Review.

PMID:
20651738
10.

Neutralization of Clostridium difficile toxin A using antibody combinations.

Demarest SJ, Hariharan M, Elia M, Salbato J, Jin P, Bird C, Short JM, Kimmel BE, Dudley M, Woodnutt G, Hansen G.

MAbs. 2010 Mar-Apr;2(2):190-8.

11.

Advances in protein therapeutics.

Woodnutt G, Violand B, North M.

Curr Opin Drug Discov Devel. 2008 Nov;11(6):754-61. Review.

PMID:
18946840
12.

Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.

Rogers J, Schoepp RJ, Schröder O, Clements TL, Holland TF, Li JQ, Li J, Lewis LM, Dirmeier RP, Frey GJ, Tan X, Wong K, Woodnutt G, Keller M, Reed DS, Kimmel BE, Tozer EC.

Protein Eng Des Sel. 2008 Aug;21(8):495-505. doi: 10.1093/protein/gzn027. Epub 2008 May 13.

13.

High-throughput cultivation of microorganisms using microcapsules.

Zengler K, Walcher M, Clark G, Haller I, Toledo G, Holland T, Mathur EJ, Woodnutt G, Short JM, Keller M.

Methods Enzymol. 2005;397:124-30.

PMID:
16260288
14.

Global proteome discovery using an online three-dimensional LC-MS/MS.

Wei J, Sun J, Yu W, Jones A, Oeller P, Keller M, Woodnutt G, Short JM.

J Proteome Res. 2005 May-Jun;4(3):801-8.

PMID:
15952726
16.

Structural characterization of the cell wall binding domains of Clostridium difficile toxins A and B; evidence that Ca2+ plays a role in toxin A cell surface association.

Demarest SJ, Salbato J, Elia M, Zhong J, Morrow T, Holland T, Kline K, Woodnutt G, Kimmel BE, Hansen G.

J Mol Biol. 2005 Mar 11;346(5):1197-206.

PMID:
15713474
17.

Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.

White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.

J Antimicrob Chemother. 2004 Jan;53 Suppl 1:i3-20. Review.

PMID:
14726431
18.

Identification of essential genes in Staphylococcus aureus using inducible antisense RNA.

Ji Y, Woodnutt G, Rosenberg M, Burnham MK.

Methods Enzymol. 2002;358:123-8. No abstract available.

PMID:
12474382
19.

Ex vivo pharmacodynamics of amoxicillin-clavulanate against beta-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics human pharmacokinetics.

Bronner S, Murbach V, Peter JD, Levêque D, Elkhaïli H, Salmon Y, Dhoyen N, Monteil H, Woodnutt G, Jehl F.

Antimicrob Agents Chemother. 2002 Dec;46(12):3782-9.

20.
21.

Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA.

Ji Y, Zhang B, Van SF, Horn, Warren P, Woodnutt G, Burnham MK, Rosenberg M.

Science. 2001 Sep 21;293(5538):2266-9.

22.

Pleuromutilins. Part 1. The identification of novel mutilin 14-carbamates.

Brooks G, Burgess W, Colthurst D, Hinks JD, Hunt E, Pearson MJ, Shea B, Takle AK, Wilson JM, Woodnutt G.

Bioorg Med Chem. 2001 May;9(5):1221-31.

PMID:
11377180
23.

Pharmacodynamics to combat resistance.

Woodnutt G.

J Antimicrob Chemother. 2000 Jul;46 Suppl T1:25-31. Review.

PMID:
10997596
24.

Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection.

Berry V, Page R, Satterfield J, Singley C, Straub R, Woodnutt G.

J Antimicrob Chemother. 2000 Apr;45 Suppl 1:87-93.

PMID:
10824038
25.

Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection.

Berry V, Page R, Satterfield J, Singley C, Straub R, Woodnutt G.

J Antimicrob Chemother. 2000 Apr;45 Suppl 1:79-85.

PMID:
10824037
26.

In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas.

Hannan PC, Woodnutt G.

J Antimicrob Chemother. 2000 Mar;45(3):367-9.

PMID:
10702559
27.

Regulated antisense RNA eliminates alpha-toxin virulence in Staphylococcus aureus infection.

Ji Y, Marra A, Rosenberg M, Woodnutt G.

J Bacteriol. 1999 Nov;181(21):6585-90.

30.
31.

Effect of protein binding on penetration of beta-lactams into rabbit peripheral lymph.

Woodnutt G, Berry V, Mizen L.

Antimicrob Agents Chemother. 1995 Dec;39(12):2678-83.

32.
33.

Bactericidal and morphological effects of amoxicillin on Helicobacter pylori.

Berry V, Jennings K, Woodnutt G.

Antimicrob Agents Chemother. 1995 Aug;39(8):1859-61.

34.

High resolution 1H NMR spectroscopic studies of the metabolism and excretion of ampicillin in rats and amoxycillin in rats and man.

Connor SC, Everett JR, Jennings KR, Nicholson JK, Woodnutt G.

J Pharm Pharmacol. 1994 Feb;46(2):128-34.

PMID:
8021801
36.
37.

Penetration of augmentin and timentin into lymph after simulation of human serum pharmacokinetics in the rabbit.

Woodnutt G, Kernutt I, Mizen L.

J Chemother. 1989 Jul;1(4 Suppl):477-8. No abstract available.

PMID:
16312492
38.

Influence of simulated human pharmacokinetics on the efficacy of temocillin against a Klebsiella pneumoniae meningitis infection in the rabbit.

Woodnutt G, Catherall EJ, Kernutt I, Mizen L.

J Chemother. 1989 Jul;1(4 Suppl):475-6. No abstract available.

PMID:
16312491
39.

Distribution and efficacy studies with ticarcillin-clavulanic acid (timentin) in experimental Klebsiella pneumoniae meningitis in rabbits.

Catherall EJ, Woodnutt G, Mizen L.

J Chemother. 1989 Jul;1(4 Suppl):80-1. No abstract available.

PMID:
16312313
41.

A study of flucloxacillin metabolites in rat urine by two-dimensional 1H, 19F COSY NMR.

Everett JR, Tyler JW, Woodnutt G.

J Pharm Biomed Anal. 1989;7(3):397-403. No abstract available.

PMID:
2488641
42.
43.

A critique of animal pharmacokinetics.

Mizen L, Woodnutt G.

J Antimicrob Chemother. 1988 Mar;21(3):273-8. No abstract available.

PMID:
3360689
44.

Pharmacokinetics and distribution of ticarcillin-clavulanic acid (Timentin) in experimental animals.

Woodnutt G, Kernutt I, Mizen L.

Antimicrob Agents Chemother. 1987 Nov;31(11):1826-30.

45.

Acetate metabolism by tissues of the rabbit.

Woodnutt G, Parker DS.

Comp Biochem Physiol B. 1986;85(2):487-90.

PMID:
2877771
46.

19F NMR spectroscopy study of the metabolites of flucloxacillin in rat urine.

Everett JR, Jennings K, Woodnutt G.

J Pharm Pharmacol. 1985 Dec;37(12):869-73.

PMID:
2868093
47.

Acetate entry rates into portal and peripheral blood in the rabbit.

Woodnutt G, Parker DS.

Proc Nutr Soc. 1979 Sep;38(2):72A. No abstract available.

PMID:
574275
48.

Rabbit liver acetyl-CoA synthetase.

Woodnutt G, Parker DS.

Biochem J. 1978 Nov 1;175(2):757-9.

Supplemental Content

Loading ...
Support Center